The Genome Editing Market size was estimated USD 6.4 billion in 2022 and is expected to reach USD 23.8 billion by 2030 at a CAGR of 17.9% during the forecast period of 2023-2030.
The strategies and procedures used to modify the genetic information of any living organism are referred to as genomic editing. The alteration of genes in numerous sites utilizing recombinant technology increases insertion precision and reduces cell toxicity. It is a set of technologies that enables scientists to modify an organism's DNA. These technologies allow for the addition, deletion, or modification of genetic information at particular sites within the genome.
Increasing applications of genomics
Future genomic engineering trends include its application in marine engineering for applications such as the development of nutraceuticals from algae. Other emerging use areas include forensic sciences and tailored medicine. While assessing fish populations, NGS can be used to identify fish larvae and eggs, as well as provide a detailed description of fish communities. Food quality and safety assessment is increasingly relying on genomics. Genome editing technologies are critical for drug development as well as the diagnosis and treatment of human genetic disorders. NGS, DNA analysis and profiling, and plant and animal genetic engineering all use genome editing. As a result of the expanding application areas of genomics, demand for genome editing technologies is likely to rise over the forecast period.
RESTRAIN
CRISPR's unintended consequences
CRISPR technology's off-target consequences are a serious constraint in gene editing. While CRISPR-Cas9 can target certain genes with astonishing precision, it can also result in unintentional alterations at places other than the intended target. This off-target activity may pose risks and complications when using CRISPR technology. It is critical to ensure appropriate targeting in order to reduce the danger of unintended alterations and associated deleterious effects. CRISPR procedures are being refined, and efforts to improve specificity and limit off-target effects are being developed. High-fidelity Cas9 variations, enhanced guide RNA design, and bioinformatics techniques have all showed promise in reducing off-target activity.
OPPORTUNITY
Gene therapy pipeline expansion
The gene editing industry's increasing pipeline for gene therapy holds tremendous prospects for breakthroughs in treating genetic abnormalities and other diseases. Gene therapy is the introduction of therapeutic genes or gene editing tools into the cells of a patient in order to rectify genetic mutations, restore normal gene activity, or introduce therapeutic genes for targeted treatment. The increasing number of gene therapy candidates in the pipeline demonstrates the potential for significant discoveries in personalized medicine and the treatment of previously incurable diseases.
CHALLENGES
Expensive equipment
The price of gene editing equipment can be significant. CRISPR-Cas9 gene editing technologies, for example, necessitate the use of specialized laboratory equipment such as DNA sequencers, heat cyclers, electroporation devices, and fluorescence microscopes. These instruments can be very expensive, with prices ranging from thousands to millions of dollars. In addition to equipment costs, obtaining high-quality reagents such as nucleases, guide RNAs, and donor templates might add to overall expenditures.
Russia's sanctions have been carefully designed to exclude and exempt the medical industry. However, some of the world's largest pharmaceutical and medical device companies have either reduced or halted their activities in Russia. Companies such as Merck, Pfizer, and Bristol-Myers Squibb have decided to halt clinical trial recruiting due to disruptions in medical consumables and materials logistics. This might dramatically lengthen the time it takes to introduce new drugs in the country.
IMPACT OF ONGOING RECESSION
Pandemics and ongoing recessions, could have a negative impact on business. The current COVID-19 pandemic has evolved over time and has resulted in a variety of responses, including government-imposed quarantines, travel restrictions, and other public health safety measures, as well as reported negative impacts on healthcare resources, facilities, and providers in Massachusetts, across the United States, and in other countries. The United States government, as well as certain other countries, have implemented travel restrictions to and from the United States and other jurisdictions, which may cause delay or prevent from performing business in a timely and efficient manner.
By Technology
Meganucleases
(CRISPR)/Cas9
TALENs/MegaTALs
ZFN
Others
In 2022, (CRISPR)/Cas9 segment is expected to held the highest market share of 43.1% during the forecast period. This technology is useful in gene therapy, drug development, and scientific study since it can correctly divide DNA strands and introduce new genetic information. Because of its simplicity, high efficiency, and precision, CRISPR/Cas9 is a popular option for genome editing, and it is appropriate for a wide range of applications. CRISPR clinical uses have gained widespread acceptance. This is evidenced by the expanding number of active clinical trials using gene-editing techniques to treat a variety of diseases such as AIDS, cancer, and hereditary problems. This technique is increasingly being used in agriculture and animal breeding applications, in addition to human health.
By Delivery Method
Ex-vivo
In-vivo
In 2022, the ex-vivo segment is expected to dominate the market growth of 3.5% during the forecast period. This can be linked to the benefits provided by this mode type, such as ease of control in DNA modification. With greater use of this delivery technology, the growing clinical trial pipeline that employs genome processing technologies has fueled the rise of the ex-vivo delivery industry. Almost 7,000 new human genetic illnesses have been discovered as a result of the success of the human genome project (HGP). While ex vivo gene editing-based gene treatments such as CAR-T have made great progress, Furthermore, most patients with genetic illnesses require in vivo treatments, which necessitate clinically accurate editing tools as well as safe and targeted delivery systems that can be scaled to aid the entire patient population, with this element adding to the segments' growth.
By Mode
Contract
In-house
In 2022, the contract segment is expected to dominate the market growth of 64.2% during the forecast period due to the high level of outsourcing efforts in the gene editing sector, which is driven by the cheaper costs and better operational flexibility provided by such activities as opposed to in-house development. The segment is likely to expand more as significant businesses in this domain increase their capabilities. For example, Crown Bioscience, Inc. cooperated with ERS Genomics Limited in December 2022 to get access to ERS's CRISPR/Cas9 patent portfolio and expand its market presence in the gene editing arena. Such activities are projected to increase outsourcing prospects in the genome editing arena, which will benefit market growth.
By Application
Genetic Engineering
Cell Line Engineering
Animal Genetic Engineering
Plant Genetic Engineering
Others
Clinical Applications
Diagnostics
Therapy Development
In 2022, the genetic engineering segment is expected to dominate the market growth of 68.9% during the forecast period. The fast increasing field of gene and stem cell therapy accounts for the lion's share. The use of CRISPR gene editing in human induced pluripotent stem cell (hiPSC)-related programs has significant implications in stem cell research for the treatment of a variety of disorders.
By End User
Biotechnology & Pharmaceutical Companies
Academic & Government Research Institutes
Contract Research Organizations
In 2022, the biotechnology & pharmaceutical companies segment is expected to dominate the market growth of 68.9% during the forecast period due to the presence of an increasing number of research efforts for novel treatment development is the most important factor influencing income generating. Furthermore, big pharmaceutical firms are cooperating with emerging firms to create breakthrough technologies. Revenue growth is being driven mostly by increased research and development efforts for novel therapies. Furthermore, a rise in strategic advancements by leading industry competitors is expected to drive market expansion. CRISPR Therapeutics AG and Capsida Biotherapeutics Inc., for example, announced a strategic collaboration in January 2022 to develop novel gene therapies using CRISPR/Cas9 technology to treat diverse diseases. Capsida will donate its adeno-associated virus (AAV) delivery technology, while CRISPR Therapeutics will contribute its genome editing knowledge.
North America held a significant market share of over 48.2% in 2022 owing to increased spending in the research and development of gene editing technologies. The region is expected to retain its dominance during the projected time due to the presence of various biotechnology and pharmaceutical companies working on developing genome editing technologies.
Asia-Pacific is witness to expand fastest CAGR rate of 19.8% during the forecast period due to China is the Asia Pacific region's largest market for genome editing technology, owing to government programs fostering the growth of genomic research. Also, the region's genome editing industry is poised for expansion, thanks to the Chinese government's increased emphasis on precision medicine and the existence of significant businesses such as BGI and Hebei Senlang Biotechnology. Furthermore, rising R&D expenditure, an increase in the prevalence of genetic illnesses, and government initiatives to encourage genomic research are all expected to propel the global market for genome editing to significant development in the coming years.
REGIONAL COVERAGE
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
The major key players Merck KGaA, Cibus, Recombinetics, Inc., Sangamo, Precision Biosciences, CRISPR Therapeutics, Intellia Therapeutics, Inc., Caribou Biosciences, Inc., AstraZeneca, Takara Bio USA, Horizon Discovery Group plc, Integrated DNA Technologies, Inc., Egenesis Inc., GenScript, New England Biolabs, OriGene Technologies, Inc., Lonza, Thermo Fisher Scientific, Inc., and Others.
Thermo Fisher Scientific, in April 2022, Thermo Fisher Scientific has released a new Gibco CTS TrueCut Cas9 Protein, as high-quality support material and documents are vital as genome editing researchers progress from fundamental research to therapeutic settings.
GenScript, in February 2023, GenScript (China) announced the development of its Singapore plant to provide a premium gene synthesis service. This represents a significant increase of the company's sophisticated gene-synthesis capabilities and enables GenScript to achieve the service levels required for the development of innovative vaccines and treatments in life sciences.
Thermo Fisher Scientific (US), in November 2022, Thermo Fisher Scientific (US) announced the debut of the Gibco CTS AAV-MAX Helper-Free AAV Production System, an all-in-one solution appropriate for commercial and clinical applications involving AAV-based gene treatments.
Lonza (Switzerland), in June 2022, Lonza (Switzerland) and Adva signed a license deal that will allow Adva to create innovative solutions for the cell and gene therapies industry.
| Report Attributes | Details |
| Market Size in 2022 | US$ 6.4 Billion |
| Market Size by 2030 | US$ 23.8 Billion |
| CAGR | CAGR of 17.9 % From 2023 to 2030 |
| Base Year | 2022 |
| Forecast Period | 2023-2030 |
| Historical Data | 2019-2021 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Technology (Meganucleases, (CRISPR)/Cas9, TALENs/MegaTALs, ZFN, Others) • By Delivery Method (Ex-vivo, In-vivo) • By Mode (Contract, In-house) • By Application (Genetic Engineering, Clinical Applications) • By End User (Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, Contract Research Organizations) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) |
| Company Profiles | Merck KGaA, Cibus, Recombinetics, Inc., Sangamo, Precision Biosciences, CRISPR Therapeutics, Intellia Therapeutics, Inc., Caribou Biosciences, Inc., AstraZeneca, Takara Bio USA, Horizon Discovery Group plc, Integrated DNA Technologies, Inc., Egenesis Inc., GenScript, New England Biolabs, OriGene Technologies, Inc., Lonza, Thermo Fisher Scientific, Inc. |
| Key Drivers | • Increasing applications of genomics |
| Market Opportunity | • Gene therapy pipeline expansion |
Ans: genome editing market is anticipated to expand by 17.9% from 2023 to 2030.
Ans: Genome editing market size was expected to grow USD 23.8 billion by 2030.
Ans: Genome editing market size was valued at USD 6.4 billion in 2022.
Ans: North America is dominating the market.
Ans: Expensive equipment is the big challenge for genome editing market.
TABLE OF CONTENT
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 Impact of the Russia-Ukraine War
4.2 Impact of Ongoing Recession
4.2.1 Introduction
4.2.2 Impact on major economies
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.2.2.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4.2.2.9 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Genome Editing Market Segmentation, By Technology
8.1 Meganucleases
8.2 (CRISPR)/Cas9
8.3 TALENs/MegaTALs
8.4 ZFN
8.5 Others
9. Genome Editing Market Segmentation, By Delivery Method
9.1 Ex-vivo
9.2 In-vivo
10. Genome Editing Market Segmentation, By Mode
10.1 Contract
10.2 In-house
11. Genome Editing Market Segmentation, By Application
11.1 Genetic Engineering
11.1.1 Cell Line Engineering
11.1.2 Animal Genetic Engineering
11.1.3 Plant Genetic Engineering
11.2 Clinical Applications
11.2.1 Diagnostics
11.2.2 Therapy Development
12. Genome Editing Market Segmentation, By End user
12.1 Biotechnology & Pharmaceutical Companies
12.2 Academic & Government Research Institutes
12.3 Contract Research Organizations
13. Regional Analysis
13.1 Introduction
13.2 North America
13.2.1 North America Genome Editing Market by Country
13.2.2 North America Genome Editing Market by Technology
13.2.3 North America Genome Editing Market by Delivery Method
13.2.4 North America Genome Editing Market by Mode
13.2.5 North America Genome Editing Market by Application
13.2.6 North America Genome Editing Market by End user
13.2.7 USA
13.2.7.1 USA Genome Editing Market by Technology
13.2.7.2 USA Genome Editing Market by Delivery Method
13.2.7.3 USA Genome Editing Market by Mode
13.2.7.4 USA Genome Editing Market by Application
13.2.7.5 USA Genome Editing Market by End user
13.2.8 Canada
13.2.8.1 Canada Genome Editing Market by Technology
13.2.8.2 Canada Genome Editing Market by Delivery Method
13.2.8.3 Canada Genome Editing Market by Mode
13.2.8.4 Canada Genome Editing Market by Application
13.2.8.5 Canada Genome Editing Market by End user
13.2.9 Mexico
13.2.9.1 Mexico Genome Editing Market by Technology
13.2.9.2 Mexico Genome Editing Market by Delivery Method
13.2.9.3 Mexico Genome Editing Market by Mode
13.2.9.4 Mexico Genome Editing Market by Application
13.2.9.5 Mexico Genome Editing Market by End user
13.3 Europe
13.3.1 Eastern Europe
13.3.1.1 Eastern Europe Genome Editing Market by Country
13.3.1.2 Eastern Europe Genome Editing Market by Technology
13.3.1.3 Eastern Europe Genome Editing Market by Delivery Method
13.3.1.4 Eastern Europe Genome Editing Market by Mode
13.3.1.5 Eastern Europe Genome Editing Market by Application
13.3.1.6 Eastern Europe Genome Editing Market by End user
13.3.1.7 Poland
13.3.1.7.1 Poland Genome Editing Market by Technology
13.3.1.7.2 Poland Genome Editing Market by Delivery Method
13.3.1.7.3 Poland Genome Editing Market by Mode
13.3.1.7.4 Poland Genome Editing Market by Application
13.3.1.7.5 Poland Genome Editing Market by End user
13.3.1.8 Romania
13.3.1.8.1 Romania Genome Editing Market by Technology
13.3.1.8.2 Romania Genome Editing Market by Delivery Method
13.3.1.8.3 Romania Genome Editing Market by Mode
13.3.1.8.4 Romania Genome Editing Market by Application
13.3.1.8.5 Romania Genome Editing Market by End user
13.3.1.9 Hungary
13.3.1.9.1 Hungary Genome Editing Market by Technology
13.3.1.9.2 Hungary Genome Editing Market by Delivery Method
13.3.1.9.3 Hungary Genome Editing Market by Mode
13.3.1.9.4 Hungary Genome Editing Market by Application
13.3.1.9.5 Hungary Genome Editing Market by End user
13.3.1.10 Turkey
13.3.1.10.1 Turkey Genome Editing Market by Technology
13.3.1.10.2 Turkey Genome Editing Market by Delivery Method
13.3.1.10.3 Turkey Genome Editing Market by Mode
13.3.1.10.4 Turkey Genome Editing Market by Application
13.3.1.10.5 Turkey Genome Editing Market by End user
13.3.1.11 Rest of Eastern Europe
13.3.1.11.1 Rest of Eastern Europe Genome Editing Market by Technology
13.3.1.11.2 Rest of Eastern Europe Genome Editing Market by Delivery Method
13.3.1.11.3 Rest of Eastern Europe Genome Editing Market by Mode
13.3.1.11.4 Rest of Eastern Europe Genome Editing Market by Application
13.3.1.11.5 Rest of Eastern Europe Genome Editing Market by End user
13.3.2 Western Europe
13.3.2.1 Western Europe Genome Editing Market by Country
13.3.2.2 Western Europe Genome Editing Market by Technology
13.3.2.3 Western Europe Genome Editing Market by Delivery Method
13.3.2.4 Western Europe Genome Editing Market by Mode
13.3.2.5 Western Europe Genome Editing Market by Application
13.3.2.6 Western Europe Genome Editing Market by End user
13.3.2.7 Germany
13.3.2.7.1 Germany Genome Editing Market by Technology
13.3.2.7.2 Germany Genome Editing Market by Delivery Method
13.3.2.7.3 Germany Genome Editing Market by Mode
13.3.2.7.4 Germany Genome Editing Market by Application
13.3.2.7.5 Germany Genome Editing Market by End user
13.3.2.8 France
13.3.2.8.1 France Genome Editing Market by Technology
13.3.2.8.2 France Genome Editing Market by Delivery Method
13.3.2.8.3 France Genome Editing Market by Mode
13.3.2.8.4 France Genome Editing Market by Application
13.3.2.8.5 France Genome Editing Market by End user
13.3.2.9 UK
13.3.2.9.1 UK Genome Editing Market by Technology
13.3.2.9.2 UK Genome Editing Market by Delivery Method
13.3.2.9.3 UK Genome Editing Market by Mode
13.3.2.9.4 UK Genome Editing Market by Application
13.3.2.9.5 UK Genome Editing Market by End user
13.3.2.10 Italy
13.3.2.10.1 Italy Genome Editing Market by Technology
13.3.2.10.2 Italy Genome Editing Market by Delivery Method
13.3.2.10.3 Italy Genome Editing Market by Mode
13.3.2.10.4 Italy Genome Editing Market by Application
13.3.2.10.5 Italy Genome Editing Market by End user
13.3.2.11 Spain
13.3.2.11.1 Spain Genome Editing Market by Technology
13.3.2.11.2 Spain Genome Editing Market by Delivery Method
13.3.2.11.3 Spain Genome Editing Market by Mode
13.3.2.11.4 Spain Genome Editing Market by Application
13.3.2.11.5 Spain Genome Editing Market by End user
13.3.2.12 The Netherlands
13.3.2.12.1 Netherlands Genome Editing Market by Technology
13.3.2.12.2 Netherlands Genome Editing Market by Delivery Method
13.3.2.12.3 Netherlands Genome Editing Market by Mode
13.3.2.12.4 Netherlands Genome Editing Market by Application
13.3.2.12.5 Netherlands Genome Editing Market by End user
13.3.2.13 Switzerland
13.3.2.13.1 Switzerland Genome Editing Market by Technology
13.3.2.13.2 Switzerland Genome Editing Market by Delivery Method
13.3.2.13.3 Switzerland Genome Editing Market by Mode
13.3.2.13.4 Switzerland Genome Editing Market by Application
13.3.2.13.5 Switzerland Genome Editing Market by End user
13.3.2.14 Austria
13.3.2.14.1 Austria Genome Editing Market by Technology
13.3.2.14.2 Austria Genome Editing Market by Delivery Method
13.3.2.14.3 Austria Genome Editing Market by Mode
13.3.2.14.4 Austria Genome Editing Market by Application
13.3.2.14.5 Austria Genome Editing Market by End user
13.3.2.15 Rest of Western Europe
13.3.2.15.1 Rest of Western Europe Genome Editing Market by Technology
13.3.2.15.2 Rest of Western Europe Genome Editing Market by Delivery Method
13.3.2.15.3 Rest of Western Europe Genome Editing Market by Mode
13.3.2.15.4 Rest of Western Europe Genome Editing Market by Application
13.3.2.15.5 Rest of Western Europe Genome Editing Market by End user
13.4 Asia-Pacific
13.4.1 Asia Pacific Genome Editing Market by Country
13.4.2 Asia Pacific Genome Editing Market by Technology
13.4.3 Asia Pacific Genome Editing Market by Delivery Method
13.4.4 Asia Pacific Genome Editing Market by Mode
13.4.5 Asia Pacific Genome Editing Market by Application
13.4.6 Asia Pacific Genome Editing Market by End user
13.4.7 China
13.4.7.1 China Genome Editing Market by Technology
13.4.7.2 China Genome Editing Market by Delivery Method
13.4.7.3 China Genome Editing Market by Mode
13.4.7.4 China Genome Editing Market by Application
13.4.7.5 China Genome Editing Market by End user
13.4.8 India
13.4.8.1 India Genome Editing Market by Technology
13.4.8.2 India Genome Editing Market by Delivery Method
13.4.8.3 India Genome Editing Market by Mode
13.4.8.4 India Genome Editing Market by Application
13.4.8.5 India Genome Editing Market by End user
13.4.9 Japan
13.4.9.1 Japan Genome Editing Market by Technology
13.4.9.2 Japan Genome Editing Market by Delivery Method
13.4.9.3 Japan Genome Editing Market by Mode
13.4.9.4 Japan Genome Editing Market by Application
13.4.9.5 Japan Genome Editing Market by End user
13.4.10 South Korea
13.4.10.1 South Korea Genome Editing Market by Technology
13.4.10.2 South Korea Genome Editing Market by Delivery Method
13.4.10.3 South Korea Genome Editing Market by Mode
13.4.10.4 South Korea Genome Editing Market by Application
13.4.10.5 South Korea Genome Editing Market by End user
13.4.11 Vietnam
13.4.11.1 Vietnam Genome Editing Market by Technology
13.4.11.2 Vietnam Genome Editing Market by Delivery Method
13.4.11.3 Vietnam Genome Editing Market by Mode
13.4.11.4 Vietnam Genome Editing Market by Application
13.4.11.5 Vietnam Genome Editing Market by End user
13.4.12 Singapore
13.4.12.1 Singapore Genome Editing Market by Technology
13.4.12.2 Singapore Genome Editing Market by Delivery Method
13.4.12.3 Singapore Genome Editing Market by Mode
13.4.12.4 Singapore Genome Editing Market by Application
13.4.12.5 Singapore Genome Editing Market by End user
13.4.13 Australia
13.4.13.1 Australia Genome Editing Market by Technology
13.4.13.2 Australia Genome Editing Market by Delivery Method
13.4.13.3 Australia Genome Editing Market by Mode
13.4.13.4 Australia Genome Editing Market by Application
13.4.13.5 Australia Genome Editing Market by End user
13.4.14 Rest of Asia-Pacific
13.4.14.1 APAC Genome Editing Market by Technology
13.4.14.2 APAC Genome Editing Market by Delivery Method
13.4.14.3 APAC Genome Editing Market by Mode
13.4.14.4 APAC Genome Editing Market by Application
13.4.14.5 APAC Genome Editing Market by End user
13.5 The Middle East & Africa
13.5.1 Middle East
13.5.1.1 Middle East Genome Editing Market By country
13.5.1.2 Middle East Genome Editing Market by Technology
13.5.1.3 Middle East Genome Editing Market by Delivery Method
13.5.1.4 Middle East Genome Editing Market by Mode
13.5.1.5 Middle East Genome Editing Market by Application
13.5.1.6 Middle East Genome Editing Market by End user
13.5.1.7 UAE
13.5.1.7.1 UAE Genome Editing Market by Technology
13.5.1.7.2 UAE Genome Editing Market by Delivery Method
13.5.1.7.3 UAE Genome Editing Market by Mode
13.5.1.7.4 UAE Genome Editing Market by Application
13.5.1.7.5 UAE Genome Editing Market by End user
13.5.1.8 Egypt
13.5.1.8.1 Egypt Genome Editing Market by Technology
13.5.1.8.2 Egypt Genome Editing Market by Delivery Method
13.5.1.8.3 Egypt Genome Editing Market by Mode
13.5.1.8.4 Egypt Genome Editing Market by Application
13.5.1.8.5 Egypt Genome Editing Market by End user
13.5.1.9 Saudi Arabia
13.5.1.9.1 Saudi Arabia Genome Editing Market by Technology
13.5.1.9.2 Saudi Arabia Genome Editing Market by Delivery Method
13.5.1.9.3 Saudi Arabia Genome Editing Market by Mode
13.5.1.9.4 Saudi Arabia Genome Editing Market by Application
13.5.1.9.5 Saudi Arabia Genome Editing Market by End user
13.5.1.10 Qatar
13.5.1.10.1 Qatar Genome Editing Market by Technology
13.5.1.10.2 Qatar Genome Editing Market by Delivery Method
13.5.1.10.3 Qatar Genome Editing Market by Mode
13.5.1.10.4 Qatar Genome Editing Market by Application
13.5.1.10.5 Qatar Genome Editing Market by End user
13.5.1.11 Rest of Middle East
13.5.1.11.1 Rest of Middle East Genome Editing Market by Technology
13.5.1.11.2 Rest of Middle East Genome Editing Market by Delivery Method
13.5.1.11.3 Rest of Middle East Genome Editing Market by Mode
13.5.1.11.4 Rest of Middle East Genome Editing Market by Application
13.5.1.11.5 Rest of Middle East Genome Editing Market by End user
13.5.2 Africa
13.5.2.1 Africa Genome Editing Market by Country
13.5.2.2 Africa Genome Editing Market by Technology
13.5.2.3 Africa Genome Editing Market by Delivery Method
13.5.2.4 Africa Genome Editing Market by Mode
13.5.2.5 Africa Genome Editing Market by Application
13.5.2.6 Africa Genome Editing Market by End user
13.5.2.7 Nigeria
13.5.2.7.1 Nigeria Genome Editing Market by Technology
13.5.2.7.2 Nigeria Genome Editing Market by Delivery Method
13.5.2.7.3 Nigeria Genome Editing Market by Mode
13.5.2.7.4 Nigeria Genome Editing Market by Application
13.5.2.7.5 Nigeria Genome Editing Market by End user
13.5.2.8 South Africa
13.5.2.8.1 South Africa Genome Editing Market by Technology
13.5.2.8.2 South Africa Genome Editing Market by Delivery Method
13.5.2.8.3 South Africa Genome Editing Market by Mode
13.5.2.8.4 South Africa Genome Editing Market by Application
13.5.2.8.5 South Africa Genome Editing Market by End user
13.5.2.9 Rest of Africa
13.5.2.9.1 Rest of Africa Genome Editing Market by Technology
13.5.2.9.2 Rest of Africa Genome Editing Market by Delivery Method
13.5.2.9.3 Rest of Africa Genome Editing Market by Mode
13.5.2.9.4 Rest of Africa Genome Editing Market by Application
13.5.2.9.5 Rest of Africa Genome Editing Market by End user
13.6 Latin America
13.6.1 Latin America Genome Editing Market by Country
13.6.2 Latin America Genome Editing Market by Technology
13.6.3 Latin America Genome Editing Market by Delivery Method
13.6.4 Latin America Genome Editing Market by Mode
13.6.5 Latin America Genome Editing Market by Application
13.6.6 Latin America Genome Editing Market by End user
13.6.7 Brazil
13.6.7.1 Brazil Genome Editing Market by Technology
13.6.7.2 Brazil Africa Genome Editing Market by Delivery Method
13.6.7.3 Brazil Genome Editing Market by Mode
13.6.7.4 Brazil Genome Editing Market by Application
13.6.7.5 Brazil Genome Editing Market by End user
13.6.8 Argentina
13.6.8.1 Argentina Genome Editing Market by Technology
13.6.8.2 Argentina Genome Editing Market by Delivery Method
13.6.8.3 Argentina Genome Editing Market by Mode
13.6.8.4 Argentina Genome Editing Market by Application
13.6.8.5 Argentina Genome Editing Market by End user
13.6.9 Colombia
13.6.9.1 Colombia Genome Editing Market by Technology
13.6.9.2 Colombia Genome Editing Market by Delivery Method
13.6.9.3 Colombia Genome Editing Market by Mode
13.6.9.4 Colombia Genome Editing Market by Application
13.6.9.5 Colombia Genome Editing Market by End user
13.6.10 Rest of Latin America
13.6.10.1 Rest of Latin America Genome Editing Market by Technology
13.6.10.2 Rest of Latin America Genome Editing Market by Delivery Method
13.6.10.3 Rest of Latin America Genome Editing Market by Mode
13.6.10.4 Rest of Latin America Genome Editing Market by Application
13.6.10.5 Rest of Latin America Genome Editing Market by End user
14 Company Profile
14.1 Merck KGaA
14.1.1Company Overview
14.1.2 Financials
14.1.3 Product/Services Offered
14.1.4 SWOT Analysis
14.1.5 The SNS View
14.2 Cibus
14.2.1Company Overview
14.2.2 Financials
14.2.3 Product/Services Offered
14.2.4 SWOT Analysis
14.2.5 The SNS View
14.3 Recombinetics, Inc.
14.3.1Company Overview
14.3.2 Financials
14.3.3 Product/Services Offered
14.3.4 SWOT Analysis
14.3.5 The SNS View
14.4 Sangamo
14.4.1Company Overview
14.4.2 Financials
14.4.3 Product/Services Offered
14.4.4 SWOT Analysis
14.4.5 The SNS View
14.5 Precision Biosciences
14.5.1Company Overview
14.5.2 Financials
14.5.3 Product/Services Offered
14.5.4 SWOT Analysis
14.5.5 The SNS View
14.6 CRISPR Therapeutics
14.6.1Company Overview
14.6.2 Financials
14.6.3 Product/Services Offered
14.6.4 SWOT Analysis
14.6.5 The SNS View
14.7 Intellia Therapeutics, Inc.
14.7.1Company Overview
14.7.2 Financials
14.7.3 Product/Services Offered
14.7.4 SWOT Analysis
14.7.5 The SNS View
14.8 Caribou Biosciences Inc.
14.8.1Company Overview
14.8.2 Financials
14.8.3 Product/Services Offered
14.8.4 SWOT Analysis
14.8.5 The SNS View
14.9 AstraZeneca
14.9.1Company Overview
14.9.2 Financials
14.9.3 Product/Services Offered
14.9.4 SWOT Analysis
14.9.5 The SNS View
14.10 Takara Bio USA
14.10.1Company Overview
14.10.2 Financials
14.10.3 Product/Services Offered
14.10.4 SWOT Analysis
14.10.5 The SNS View
14.11 Horizon Discovery Group plc
14.11.1Company Overview
14.11.2 Financials
14.11.3 Product/Services Offered
14.11.4 SWOT Analysis
14.11.5 The SNS View
14.12 Integrated DNA Technologies Inc.
14.12.1Company Overview
14.12.2 Financials
14.12.3 Product/Services Offered
14.12.4 SWOT Analysis
14.12.5 The SNS View
14.13 Egenesis Inc.
14.13.1Company Overview
14.13.2 Financials
14.13.3 Product/Services Offered
14.13.4 SWOT Analysis
14.13.5 The SNS View
14.14 GenScript
14.14.1Company Overview
14.14.2 Financials
14.14.3 Product/Services Offered
14.14.4 SWOT Analysis
14.14.5 The SNS View
14.15 New England Biolabs
14.15.1Company Overview
14.15.2 Financials
14.15.3 Product/Services Offered
14.15.4 SWOT Analysis
14.15.5 The SNS View
14.16 OriGene Technologies, Inc.
14.16.1Company Overview
14.16.2 Financials
14.16.3 Product/Services Offered
14.16.4 SWOT Analysis
14.16.5 The SNS View
14.17 Lonza
14.17.1Company Overview
14.17.2 Financials
14.17.3 Product/Services Offered
14.17.4 SWOT Analysis
14.17.5 The SNS View
14.18 Thermo Fisher Scientific, Inc.
14.18.1Company Overview
14.18.2 Financials
14.18.3 Product/Services Offered
14.18.4 SWOT Analysis
14.18.5 The SNS View
15. Competitive Landscape
15.1 Competitive Bench marking
15.2 Market Share Analysis
15.3 Recent Developments
15.3.1 Industry News
15.3.2 Company News
15.3.3 Mergers & Acquisitions
16. USE Cases and Best Practices
17. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Patient Handling Equipment Market size was estimated USD 13,241 million in 2022 and is expected to reach USD 18974.67 million By 2030 at a CAGR of 4.6 % during the forecast period of 2023-2030.
The Animal Model Market size was estimated USD 2.2 billion in 2022 and is expected to reach USD 4.2 billion by 2030 at a CAGR of 8.7% during the forecast period of 2023-2030.
The Orthopedic Devices Market size was USD 34.1 Billion in 2022 and is expected to reach USD 50.38 Billion by 2030 and grow at a CAGR of 5% over the forecast period of 2023-2030.
The Health IT Security Market Size was valued at USD 12.35 billion in 2022, and is expected to reach USD 19.10 billion by 2030, and grow at a CAGR of 15.6% over the forecast period 2023-2030.
In 2023, The Diabetic Ulcer Treatment Market size amounted to USD 10.31 Billion & is estimated to reach USD 15.59 Billion by 2031 and increase at a compound annual growth rate of 5.3% between 2024 and 2031.
The Healthcare Technology Management Market size was estimated 6.92 USD billion in 2022 and is expected to reach USD 21.34 billion by 2030 at a CAGR of 15.12% during the forecast period of 2023-2030.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
